Xu Tong-Peng, Zhu Can-Hong, Zhang Jian, Xia Rui, Wu Feng-Lei, Han Liang, Shen Hua, Liu Ling-Xiang, Shu Yong-Qian
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China E-mail :
Asian Pac J Cancer Prev. 2013;14(12):7085-90. doi: 10.7314/apjcp.2013.14.12.7085.
Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of microRNA-155 are inconclusive. The aim of the present analysis was therefore to evaluate the role of miR-155 in prognosis for patients with a variety of carcinomas.
Relevant studies were identified by searching PubMed and EMBASE. Data were extracted from studies comparing overall survival (OS), recurrence-free survival (RFS) or cancer-specific survival (CSS) in patients with carcinoma with higher miR-155 expression and those with lower levels. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of miR-155 for clinical outcome were calculated.
A total of 15 studies were included. The pooled hazard ratio (HR) for OS of higher miR-155 expression in cancerous tissue was 1.89 (95% CI: 1.20-2.99, P =0.006), which could markedly predict poorer survival in general cancer. For RFS/CSS, elevated miR-155 was also associated with poor prognosis of cancer (HR= 1.50, 95% CI: 1.10-2.05, P = 0.01). On subgroup analysis, the pooled HR for OS in non-small cell lung cancer (NSCLC) was 2.09 (95% CI: 0.68-6.41, P > 0.05), but for RFS/CSS was 1.28 (95% CI: 1.05-1.55, P = 0.015), with statistical significance; the pooled HRs for OS and RFS/CSS in digestive system neoplasms were 3.04 (95% CI: 1.48-6.24, P =0.003) and 2.61 (95% CI: 1.98-3.42, P<0.05), respectively.
The results indicated that the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas.
已发表的数据表明，微小RNA（miRNA）可能在癌症中作为诊断和预后指标发挥潜在作用。关于微小RNA-155预测价值的数据尚无定论。因此，本分析的目的是评估miR-155在各种癌症患者预后中的作用。
通过检索PubMed和EMBASE确定相关研究。数据从比较miR-155表达较高和较低的癌症患者总生存期（OS）、无复发生存期（RFS）或癌症特异性生存期（CSS）的研究中提取。计算miR-155对临床结局的合并风险比（HR）和95%置信区间（CI）。
共纳入15项研究。癌组织中miR-155高表达的OS合并风险比（HR）为1.89（95%CI：1.20-2.99，P = 0.006），这可显著预测总体癌症患者较差的生存期。对于RFS/CSS，miR-155升高也与癌症预后不良相关（HR = 1.50，95%CI：1.10-2.05，P = 0.01）。亚组分析显示，非小细胞肺癌（NSCLC）中OS的合并HR为2.09（95%CI：0.68-6.41，P>0.05），但RFS/CSS的合并HR为1.28（95%CI：1.05-1.55，P = 0.015），具有统计学意义；消化系统肿瘤中OS和RFS/CSS的合并HR分别为3.04（95%CI：1.48-6.24，P = 0.003）和2.61（95%CI：1.98-3.42，P<0.05）。
结果表明，miR-155表达水平在癌症患者，尤其是非小细胞肺癌和消化系统癌症患者的预后中起作用。
